Clinical Trials Microdosing Patients 
CannaMD
SEPTEMBER 9, 2020
Published only recently, in May of 2020, this clinical trial is the first to show that microdoses of cannabis can be just as effective as much higher doses. What is microdosing? The concept of microdosing is pretty simple. The premise behind marijuana microdosing is equally straightforward. Translation?
Cannabis Law Report
JULY 25, 2022
million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Otherside Farms
JANUARY 16, 2019
Microdosing, if you have not yet heard of it, is hotter than just any ordinary trend: Science proves THC and CBD safe, with very real benefits associated with consuming very low doses regularly, as opposed to massive doses all at once. People are microdosing psychedelics, vitamins, near everything for health purposes.
The Cannigma
DECEMBER 12, 2022
Using integration or psychotherapy along with these medicines allows patients to incorporate the positive effects permanently. What is microdosing? A microdose is a dose that does not elicit a perceivable intoxicating or trip-like effect. Microdosing is possible in theory, but there are no current recommendations.
Veriheal
MARCH 20, 2023
Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Both Colorado and Oregon allow patients to take psilocybin under the supervision of regulated and licensed “healing centers.” Missouri Rep.
Cannabis Law Report
SEPTEMBER 10, 2019
The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients. Forbes reported on Hopkins researchers’ recommendation that, if psilocybin should clear Phase III clinical trials, the FDA should reclassify it from a Schedule I to a Schedule IV drug. Psychedelic Research News.
Expert insights. Personalized for you.
111 
Let's personalize your content